About Humacyte
Humacyte is a company based in Morrisville (United States) founded in 2004. It operates as a HealthTech, and Product-as-a-Service. Humacyte has raised $424.76 million across 11 funding rounds from investors including SVB, Bangkok Bank and Fresenius Medical Care. The company has 220 employees as of December 31, 2024. Humacyte offers products and services including Symvess™ and Acellular Tissue Engineered Vessel (ATEV™). Humacyte operates in a competitive market with competitors including CUTISS, Solsys Medical, Heartseed, ORTHOCON and Tissue Regenix, among others.
- Headquarter Morrisville, United States
- Employees 220 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Humacyte, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-148.7 M-34.24as on Dec 31, 2024
-
EBITDA
$-107.21 M-16.12as on Dec 31, 2024
-
Total Equity Funding
$424.76 M (USD)
in 11 rounds
-
Latest Funding Round
-
Investors
SVB
& 12 more
-
Employee Count
220
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Humacyte
Humacyte is a publicly listed company on the NASDAQ with ticker symbol HUMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Humacyte
Humacyte offers a comprehensive portfolio of products and services, including Symvess™ and Acellular Tissue Engineered Vessel (ATEV™). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Symvess™ is used for vascular trauma repair treatment.
ATEV™ is developed for hemodialysis arteriovenous access needs.
Unlock access to complete
Unlock access to complete
Funding Insights of Humacyte
Humacyte has successfully raised a total of $424.76M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Last Round
-
First Round
First Round
(01 Jun 2006)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Debt – Venture - Humacyte | Valuation |
investors |
|
| Jun, 2018 | Amount | Series D - Humacyte | Valuation | Fresenius Medical Care |
|
| Feb, 2018 | Amount | Series C - Humacyte | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Humacyte
Humacyte has secured backing from 13 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include SVB, Bangkok Bank and Fresenius Medical Care. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and holding company controlled by Len Blavatnik
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Biotech startups are incubated and funded in North Carolina.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Humacyte
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Humacyte
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Humacyte Comparisons
Competitors of Humacyte
Humacyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CUTISS, Solsys Medical, Heartseed, ORTHOCON and Tissue Regenix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Personalized skin tissue therapy is developed by CUTISS for surgeries.
|
|
| domain | founded_year | HQ Location |
Human skin allografts and dressings for wound care are supplied.
|
|
| domain | founded_year | HQ Location |
Developer of myocardial regenerative medicine for treating heart diseases
|
|
| domain | founded_year | HQ Location |
Resorbable hemostatic bone putty is developed to stop surgical bleeding.
|
|
| domain | founded_year | HQ Location |
Developer of regenerative medical devices by using cell technology
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Humacyte
Frequently Asked Questions about Humacyte
When was Humacyte founded?
Humacyte was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Where is Humacyte located?
Humacyte is headquartered in Morrisville, United States.
Is Humacyte a funded company?
Humacyte is a funded company, having raised a total of $424.76M across 11 funding rounds to date. The company's 1st funding round was a Series C of $75M, raised on Jun 01, 2006.
How many employees does Humacyte have?
As of Dec 31, 2024, the latest employee count at Humacyte is 220.
What does Humacyte do?
Humacyte is engaged in the development and manufacture of bioengineered human tissues and organs. These tissues are designed to be universally implantable, off-the-shelf, and regenerative, targeting a wide range of diseases, injuries, and chronic conditions. The companys platform supports tissue repair and replacement across various clinical needs, including vascular trauma, hemodialysis access, and investigational applications like tracheal and esophageal replacement. Solutions are built on the Acellular Tissue Engineered Vessel platform, aiming for low infection rates and broad patient accessibility in the healthcare sector.
Who are the top competitors of Humacyte?
Humacyte's top competitors include CUTISS, Acera Surgical and Heartseed.
What products or services does Humacyte offer?
Humacyte offers Symvess™ and Acellular Tissue Engineered Vessel (ATEV™).
Is Humacyte publicly traded?
Yes, Humacyte is publicly traded on NASDAQ under the ticker symbol HUMA.
Who are Humacyte's investors?
Humacyte has 13 investors. Key investors include SVB, Bangkok Bank, Fresenius Medical Care, HHS, and NCBiotech.
What is Humacyte's ticker symbol?
The ticker symbol of Humacyte is HUMA on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.